

Ref: FOI/GS/ID 7293

**Please reply to:**  
FOI Administrator  
Trust Management  
Maidstone Hospital  
Hermitage Lane  
Maidstone, Kent  
ME16 9QQ  
Email: [mtw-tr.foiadmin@nhs.net](mailto:mtw-tr.foiadmin@nhs.net)  
[www.mtw.nhs.uk](http://www.mtw.nhs.uk)

14 March 2022

## **Freedom of Information Act 2000**

I am writing in response to your request for information made under the Freedom of Information Act 2000 in relation to Multiple Myeloma.

*You asked:*

*I am investigating the use of targeted therapies in blood-related cancers.*

- 1. Could you please tell me how many patients have you treated in the last 3 months for Multiple Myeloma?*
- 2. Further, how many have received the following treatments?*

*Treatment:*

*Bortezomib [Velcade] and Dexamethasone*

*Bortezomib [Velcade], Thalidomide and Dexamethasone [known as VTD]*

*Bortezomib [Velcade], Cyclophosphamide/Melphalan and*

*Dexamethasone/Prednisolone [known as VCD or VMP]*

*Lenalidomide [Revlimid] monotherapy*

*Lenalidomide [Revlimid] and Dexamethasone*

*Lenalidomide [Revlimid], Bortezomib [Velcade] and Dexamethasone*

*Lenalidomide [Revlimid], Melphalan and Prednisolone*

*Thalidomide, Cyclophosphamide/Melphalan, and*

*Dexamethasone/Prednisolone [known as MPT or CTD]*

*Bortezomib [Velcade] monotherapy*

*Carfilzomib [Kyprolis] and Dexamethasone*

*Carfilzomib [Kyprolis], Lenalidomide [Revlimid], and Dexamethasone [known as KRD]*

*Daratumumab [Darzalex], Velcade [Bortezomib] and Dexamethasone [known as DVD]*

*Daratumumab [Darzalex], Velcade [Bortezomib], Thalidomide and Dexamethasone [known as Dara-VTd]*

*Daratumumab [Darzalex], Lenalidomide [Revlimid] and Dexamethasone*

*Daratumumab [Darzalex], Pomalidomide [Imnovid] and Dexamethasone (DaraPd)*

*Daratumumab [Darzalex] monotherapy*  
*Isatuximab [Sarclisa], Pomalidomide [Imnovid] and Dexamethasone [known as IsaPd]*  
*Isatuximab [Sarclisa], Carfilzomib [Kyprolis] and Dexamethasone [known as IsaKd]*  
*Ixazomib [Ninlaro], Lenalidomide [Revlimid] and Dexamethasone [known as IRD]*  
*Pomalidomide [Imnovid] and Dexamethasone*  
*Panobinostat [Farydak], Bortezomib [Velcade] and Dexamethasone*  
*Any other systemic anti-cancer treatment*

Trust response:

1. 12 for the period 1/12/2021-28/2/2022.
- 2.

Treatment	Patients in last 3 months
Bortezomib [Velcade] and Dexamethasone	12
Bortezomib [Velcade], Thalidomide and Dexamethasone [known as VTD]	0
Bortezomib [Velcade], Cyclophosphamide/Melphalan and Dexamethasone/Prednisolone [known as VCD or VMP]	2
Lenalidomide [Revlimid] monotherapy	18
Lenalidomide [Revlimid] and Dexamethasone	7
Lenalidomide [Revlimid], Bortezomib [Velcade] and Dexamethasone	0
Lenalidomide [Revlimid], Melphalan and Prednisolone	0
Thalidomide, Cyclophosphamide/Melphalan, and Dexamethasone/Prednisolone [known as MPT or CTD]	0
Bortezomib [Velcade] monotherapy	0
Carfilzomib [Kyprolis] and Dexamethasone	0
Carfilzomib [Kyprolis], Lenalidomide [Revlimid], and Dexamethasone [known as KRD]	2
Daratumumab [Darzalex], Velcade [Bortezomib] and Dexamethasone [known as DVD]	4
Daratumumab [Darzalex], Velcade [Bortezomib], Thalidomide and Dexamethasone [known as Dara-VTd]	0
Daratumumab [Darzalex], Lenalidomide [Revlimid] and Dexamethasone	1
Daratumumab [Darzalex], Pomalidomide [Imnovid] and Dexamethasone (DaraPd)	0
Daratumumab [Darzalex] monotherapy	7
Isatuximab [Sarclisa], Pomalidomide [Imnovid] and Dexamethasone [known as IsaPd]	7
Isatuximab [Sarclisa], Carfilzomib [Kyprolis] and Dexamethasone [known as IsaKd]	0
Ixazomib [Ninlaro], Lenalidomide [Revlimid] and Dexamethasone [known as IRD]	18
Pomalidomide [Imnovid] and Dexamethasone	0
Panobinostat [Farydak], Bortezomib [Velcade] and Dexamethasone	3
Any other systemic anti-cancer treatment	7